I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Switzerland

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology Melanoma

Melanoma

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Sep 10 / Roche and Genentech
A Phase 1b/2 Multicenter, Randomized, Umbrella Study Evaluating Novel Treatment Combinations in Melanoma (MORPHEUS-MELANOMA)
This poster describes the design of a phase 1b/2 multicenter, randomized, open-label, umbrella study (MORPHEUS-MELANOMA) to evaluate the safety, efficacy, and pharmacokinetics of various novel treatments or treatment combinations targeting multiple immune evasion mechanisms in patients with treatment-naive, resectable stage III melanoma and in patients with previously treated stage IV melanoma.
Oncology Skin Cancer Melanoma ESMO-2022

Sign up or login to unlock the full suite of MEDICALLY features
Sep 10 / Roche and Genentech
Time to Development of Central Nervous System Metastases With Atezolizumab or Placebo Combined With Vemurafenib + Cobimetinib: Updated Results From the Phase 3 IMspire150 Study
The phase 3 IMspire150 study demonstrated improved progression-free survival with first-line combination treatment with the combination of atezolizumab, vemurafenib, and cobimetinib compared with placebo, vemurafenib, and cobimetinib in patients with previously untreated BRAFV600 mutation–positive advanced melanoma. This poster describes results of an exploratory analysis to evaluate incidence and time to development of CNS metastases in the IMspire150 study.
Oncology Skin Cancer Melanoma ESMO-2022

Sign up or login to unlock the full suite of MEDICALLY features
Oct 28 / Roche and Genentech
Melanoma brain metastasis in previously treated patients by tumor mutation type
This real-world observational study evaluated the incidence of brain metastases and overall survival according to BRAF and NRAS mutational status in patients with previously-treated advanced melanoma.
Oncology Melanoma SMR-2021

Sign up or login to unlock the full suite of MEDICALLY features
Personalised Healthcare
Jun 4 / Roche and Genentech
Evaluation of Patients With Surgically Resected High-Risk Melanoma Receiving Adjuvant Therapy in Routine Clinical Practice in the US
This study assessed adjuvant treatment patterns and outcomes in patients with advanced melanoma by BRAF status and relapse location using the Flatiron Health electronic health record-derived deidentified database. The majority of patients with resected stage III melanoma, including patients who experienced relapse, initiated adjuvant treatment with checkpoint inhibitors (CPIs) vs targeted therapies (TTs) in the real-world setting. Early relapse free survival (RFS) and overall survival (OS) outcomes for patients with surgically resected stage III melanoma appear comparable with those reported in randomized clinical studies. Outcomes for patients with distant relapse after adjuvant therapy remain unfavorable and represent a continued unmet medical need.
Oncology Melanoma Real World Data - Real World Evidence ASCO-2021

Sign up or login to unlock the full suite of MEDICALLY features
Nov 9 / Roche and Genentech
Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study
The randomized controlled, phase 3 IMspire150 study showed that combination treatment with atezolizumab, vemurafenib and cobimetinib improved treatment outcomes versus placebo plus vemurafenib and cobimetinib in patients with advanced/metastatic BRAFV600 mutation-positive melanoma. This poster presents a comparative analysis of treatment benefit in terms of progression-free survival and duration of objective response in subgroups of patients defined by tumor mutation burden (TMB) and immune microenvironment. The analysis show that treatment benefit with atezolizumab, vemurafenib and cobimetinib over placebo plus vemurafenib and cobimetinib is variable and is generally more pronounced in patients whose tumors accumulate more mutations (TMB >10 mutations /Mb) or those with a pro-inflammatory tumor immune microenvironment.
Oncology Melanoma SITC-2020

Sign up or login to unlock the full suite of MEDICALLY features
Nov 9 / Roche and Genentech
Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study
The randomized controlled, phase 3 IMspire150 study showed that combination treatment with atezolizumab, vemurafenib and cobimetinib improved treatment outcomes versus placebo + vemurafenib + cobimetinib in patients with advanced/metastatic BRAFV600 mutation-positive melanoma. This poster presents results of an exploratory analysis evaluating the impact of response on survival outcomes in subgroups of patients defined by treatment response. The analysis showed that progression-free survival and overall survival were longest in patients who achieved complete response and shortest in those with stable disease, irrespective of treatment arm; in patients who achieved partial response, progression-free survival and overall survival were improved with atezolizumab + vemurafenib + cobimetinib versus placebo + vemurafenib + cobimetinib.
Oncology Melanoma SITC-2020

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.